Clinical Trials

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02420860 2026-04-15

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

113 enrolled

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

67 enrolled

Multiple Myeloma

NCT04835129 2026-03-27

IMPEDE

28 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

15 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT05730036 2026-03-06

LINKER-MM3

410 enrolled

Multiple Myeloma

NCT05981209 2026-02-02

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Phase 1 Recruiting

27 enrolled

Multiple Myeloma

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Multiple Myeloma, Recurrence

NCT02969837 2026-01-16

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

46 enrolled 10 charts

Multiple Myeloma

NCT04517851 2026-01-13

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

15 enrolled

Myeloid

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

28 enrolled

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

NCT05560399 2026-01-02

CC-220

7 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

49 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

117 enrolled

Multiple Myeloma

NCT05002816 2025-10-30

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

24 enrolled

Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

37 enrolled

Multiple Myeloma

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT03713294 2025-06-24

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

37 enrolled 11 charts

Multiple Myeloma

NCT01729091 2025-05-09

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Other hematologic neoplasmPlasma cell

72 enrolled 14 charts

Leukemia, Plasma Cell, Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT02375555 2024-10-01

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

40 enrolled 18 charts

Multiple Myeloma

NCT03000634 2024-09-05

2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

Multiple Myeloma

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

No longer available

Multiple Myeloma

NCT02843074 2023-12-05

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Other hematologic neoplasmPlasma cell

53 enrolled 14 charts

Multiple Myeloma, Hematologic Neoplasms

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

No longer available

Other hematologic neoplasmPlasma cell

Multiple Myeloma

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

42 enrolled

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT02279394 2023-06-09

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

51 enrolled 14 charts

Phase 3 Active not recruiting

Smoldering Multiple Myeloma

NCT03948035 2023-05-06

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

576 enrolled

Multiple Myeloma

NCT03411031 2023-03-29

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase 2 Terminated

18 enrolled 11 charts

Multiple Myeloma

NCT02726581 2023-03-27

CheckMate 602

170 enrolled 16 charts

Multiple Myeloma

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2 Unknown

53 enrolled

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT02654132 2022-11-01

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

117 enrolled 14 charts

Multiple Myeloma

NCT01335399 2022-09-30

ELOQUENT - 1

748 enrolled 15 charts

Multiple Myeloma

NCT02272803 2022-06-22

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

82 enrolled 13 charts

Multiple Myeloma

NCT01239797 2022-06-01

ELOQUENT - 2

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05170789 2022-05-04

ESdRRMM

Multiple Myeloma, Recurrence

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Phase 2 Terminated

13 enrolled

Multiple Myeloma

NCT03126617 2021-11-29

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

No longer available

Multiple Myeloma

NCT02495922 2021-09-10

GMMG-HD6

564 enrolled

Multiple Myeloma

NCT04584307 2021-08-23

Immuno-POWER

Multiple Myeloma

NCT02612779 2021-07-02

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

74 enrolled 14 charts

Multiple Myeloma

NCT03003728 2020-07-10

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Multiple Myeloma

NCT03393273 2019-07-17

IFM2016-03

Multiple Myeloma

NCT02159365 2019-07-16

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

84 enrolled 11 charts